Background: CHL1 gene (also known as CALL) on 3p26.3 encodes a one-pass trans-membrane cell adhesion molecule (CAM). Previously CAMs of this type, including L1, were shown to be involved in cancer growth and metastasis.
Introduction
Cancer-associated genes fall into two main categories: cancercausing genes that drive malignant transformation and maintain tumor growth, and cancer progression genes that orchestrate local invasion and further spread of metastatic cells and growth of distant metastases [1, 2, 3] . The CHL1 gene -close homolog of L1, also known as CALL -cell adhesion L1-like (GenBank Accession No. NM_006614.2) encodes a one-pass trans-membrane cell adhesion molecule (CAM) capable of both homotypic and heterotypic binding. The protein encoded by this gene is a member of the L1 gene family of neural cell adhesion molecules. It is a neural recognition molecule that may be involved in signal transduction pathways. CHL1 is expressed in normal tissues besides the brain and is expressed in a variety of human cancer cell lines and primary tumor tissues [4, 5] . It was also shown that the gene is involved in general cognitive activities (g/IQ) [6, 7] and some neurological diseases (i.e. schizophrenia [8] ). The deletion of one copy of this gene may be responsible for mental defects in patients with 3p-syndrome. Recently several CAMs including L1 were shown to be involved in cancer growth and metastasis [9, 10] . CHL1 is located at 3p26, a region that is shown to harbor a candidate for prostate cancer susceptibility in Finnish prostate cancer families, although no mutations were detected in the coding part of the gene [11] . Thus, these reports suggest that CHL1 plays a role in cancer development [12] , not only in neuronal activities.
Previously, in collaboration with Dr. Helen S. Smith, we performed a deletion mapping of the short arm of chromosome 3 on a panel of breast cancers and delineated three regions as harboring breast cancer candidate tumor suppressor genes (TSG), namely, 3p24-26, 3p21-22, and 3p12-13 [13, 14, 15, 16] . Then we cloned the CHL1 (CALL) gene in 1997/1998 and analyzed its expression in mouse development and performed extensive bioinformatics analysis [5] .
Here we provided a comprehensive study of CHL1 mRNA expression using two methods. Qualitative analysis was performed using Clontech Cancer Profiling Arrays, and further real time quantitative PCR (RT-qPCR) was employed for validation of the microarray data for three major cancer types: non-small cell lung cancer (NSCLC), breast cancer (BC), and renal cell carcinomas (RCC). Our results suggested a dual role of the CHL1 in tumorigenesis: it may contribute to initial tumor growth and then to progression and finally tumor spread/metastasis. The data further supported the role of CHL1 as a potentially novel specific biomarker in the early pathogenesis of two major histological types of renal cancer.
The work is dedicated to the memory of Dr. Helen S. Smith.
Results

In silico analysis of CHL1 expression in normal and tumor tissues
The vast public expression databases allow to detect and quantify the expression of most if not all known RefSeq genes (,20,000) in normal and tumor tissues. We used several public web-based servers to analyze mouse and human CHL1 expression [17, 18, 19, 20] . The data shows that CHL1 is expressed in many normal adult and fetal tissues besides the brain and peripheral nervous system [17, 19] . Variable expression was seen in many tumors; it was especially high in a melanoma cell line G361. According to Oncomine [18] preliminary data based on microarray analysis, the CHL1 expression also varies in several major cancer types -renal [21, 22] , cervical [23] , colon [24, 25] , ovary [26] , lung [27, 28] , stomach [29] and breast [30, 31] cancer. The Oncomine also showed co-expression of CHL1 with another known cancer metastasis-associated gene, lysyl oxidase (LOX) [32] in metastatic melanoma.
Investigation of CHL1 expression with Cancer Profiling Arrays
We used Cancer Profiling Arrays I and II (Clontech) to test the CHL1 expression in a large sample of human primary tumors including breast, lung, kidney, ovary, colon, stomach and others (Fig. 1) . Only 395 samples of 486, including 90 metastatic tumors and 12 metastases were informative. We first showed that the change of CHL1 expression in all studied tumors compared to the matched non-cancerous (normal) tissues was statistically significant (P,0.05, Fisher exact test or x 2 criteria). Down-regulation. As demonstrated by Cancer Profiling Arrays data in Figures 1 and 2 , a high percentage of patients displayed a down-regulation of CHL1 expression in breast, kidney, rectum, colon, thyroid, stomach, skin, small intestine, bladder, vulva and pancreatic cancer. The results of the microarray data analysis were presented for 11 types of cancer in Table 1 . In total, a statistically significant decrease of CHL1 expression was found in breast cancer -71% (45 of 63 cases), colon -48% (23 of 48), rectum -50% (14 of 28), thyroid -69% (11 of 16), kidney -75% (21 of 28) and small intestine -67% (6 of 9) cancers. Importantly, a statistically significant increase of down-regulation frequency was shown in samples with metastases compared to samples without metastases in colon (83% vs. 36%, P = 0.01) and rectum (75% vs. 31%, P = 0.05) cancers. The same tendency was found in ovary cancer (60% vs. 19%, P = 0.17).
Up-regulation. The CHL1 up-regulation (frequency from 20% to 100%) was found in lung, ovary, uterus, liver, skin, prostate, stomach, cervix and trachea cancers. However, the increase of the CHL1 mRNA level was statistically significant only in lung cancer 264% (16 of 25, P,0.01). The majority of such cases (14 of 22, P,0.01) were found in different histotypes of NSCLC (ADC, BAC, SCC) at the Stage I. Also we observed several cases of CHL1 up-regulation in metastatic tumors (stomach, lung, trachea, ovary and uterus, Table 1 ). Thus, the cases with CHL1 up-regulation could serve as examples of CHL1 involvement both in initial and possibly in further progression and invasive tumor growth.
Deregulation. In uterus and ovary cancer the frequency of up-and down-regulation was close (41% and 30%, 46% and 27%, respectively). In ovary cancer the down-regulation was a prevalent event (52%) in samples without metastases, on the contrary the upregulation was prevalent (60%) in the group of metastatic tumors. In stomach cancer a statistically significant change of CHL1 expression (both up-and down-regulation) was shown in the group with metastases relative to the group without metastases (88% vs. 45%, P = 0.02).
Metastases. We observed re-expression of the CHL1 in 4 of 12 metastases (first coordinate) along with low CHL1 mRNA level in primary tumor (second coordinate): in ovary (24K/24L), colon (14O/14P, 14V/14W) and breast (4I/4J, Fig. 1, Array I ). In addition, we also found silencing of the gene expression in both metastasis and primary tumors, for example, breast cancer (4G/ 4H, 4K/4L).
The CHL1 expression in breast, lung and renal cancer tissues studied using RT-qPCR
The CHL1 mRNA content was decreased in the majority of studied tumor samples compared to normal samples but in some tumor samples the CHL1 expression was up-regulated ( Fig. 3 . A, B and C).
Breast cancer (BC). We found that the CHL1 mRNA level was decreased in 61% (14 of 23, P,0.03), increased in 22% (5 of 23) and not changed in 17% (4 of 23) of samples. Maximal decrease of the CHL1 mRNA level was 20-fold, maximal increase was 34-fold. There was no evident correlation between the change of the CHL1 expression and the tumor progression (Fig. 3 A) .
Non-small cell lung cancer (NSCLC). The CHL1 mRNA level was decreased in 60% (18 of 30, P,0.02) and was normal in 33% (10 of 30), i.e. less than 2-fold changes. The decrease or increase of the mRNA level was detected neither in lung noncancerous (normal) matched tissues nor in tissues from cancer free healthy donors. However, for two histological subtypes of NSCLC (ADC and SCC) the frequency of the mRNA changes was different. Down-regulation was observed in 38% (5 of 14) of ADC samples. The increase of the CHL1 mRNA (7-fold) was detected only in one ADC sample. On the contrary, in SCC samples the CHL1 expression was significantly decreased in 81%, (13 of 16, P,0.02). LD (level of mRNA decrease) varied from 2 to 100-fold in ADC and from 2 to 44-fold in SCC. There was a more significant increase of FD (frequency of mRNA decreases) values in SCC as compared to ADC (81% vs. 38%, P = 0.02) without noticeable association with tumor progression (Fig. 3, B and Table 2 ).
Clear cell renal cell carcinoma (CC-RCC), papillary renal cell carcinoma (pRCC) and renal carcinoma cell lines. A significant decrease (from 3 to 302-fold) of CHL1 mRNA was detected in 87% (26 of 30, P,0.01) of CC-RCC specimens and 89% (8 of 9, P,0.02) of pRCC specimens with LD av (geometric mean of LD) equal to 18 and 19-fold respectively (Fig. 3, C) . Therefore we could conclude that the frequency and the average level of the CHL1 expression decrease were similar for two major histological types of renal cancer, CC-RCC and pRCC. The LD av value was significant in all RCC tumors at all developmental stages independent of metastasis presence (Table 3 ). In CC-RCC with or without metastases, the FD and LD av values were similar.
The estimates of the CHL1 mRNA levels in seven renal cancer cell lines revealed strong down-regulation of this gene: 80-fold (Caki2, KRC/Y), about 1000-fold (TK164) and total silencing (TK10, KH39, HN4, Caki1, Fig. 4 ).
Comparison of microarrays and RT-qPCR data for breast, renal and lung cancer
The microarray data for 61 BC, 23 RCC and 25 NSCLC samples were compared with RT-qPCR data for 23 BC, 30 CC-RCC and 30 NSCLC samples. In our array study a significant CHL1 down-regulation was shown for most of RCC samples; upregulation was observed in 3 cases only. Our results also showed the down-regulation of CHL1 in most of BC samples independent of the presence of metastases and up-regulation in 7 tumors only. Almost the same results were obtained using RT-qPCR. There were similarities between array and quantitative data for renal and breast cancer (Table 4) .
Cancer Profiling Arrays I and II include a very heterogeneous group of lung cancer with different histological subtypes: BAC, ADC, SCC, carcinoid with Stage I and II, only two metastatic tumors and limited number of specimens of each subtype. Overall, there were 15 SCC and 5 ADC which we could compare with RT-qPCR data. We found an up-regulation in 11 SCC (6 of 11 were identified as Stage I) and 4 ADC (3 ADC were Stage I as well); down-regulation in 2 SCC (13%) and 1 ADC (25%, Fig. 1 ). Recently, we showed an upregulation of several TSG on 3p in lung ADC at Stage I. These tumors were characterized with high differentiation grade [33] . On the other hand, according to the RT-qPCR data frequency of decreased expression was 38% (5 of 14 cases) in ADC and 81% (13 of 16 cases, P,0.02) in SCC (see Table 2 ). An up-regulation was detected only in 7% (1 of 14 cases) ADC and never in SCC.
Discussion
CHL1, located at 3p26.1, belongs to the family of cell adhesion molecules (CAM) -cell surface proteins mediating cell-cell and cell-matrix interactions. Alterations in CAM expression (including CHL1) and functions have been implicated in development of different tumor types, for example, melanoma [34] , ovary [9, 35] , prostate [11] and colon cancer [36] . According to [9] , the evaluation of LOH patterns in serous epithelial ovarian cancer (EOC) suggested that CHL1 is a tumor suppressor candidate (TSG). The studies published by us and other authors (see Introduction) suggested that the CHL1 gene could be one of the putative tumor suppressor genes localized on human chromosome 3 [12] . However, overexpression of CHL1 was observed in serous EOC samples [9] . Furthermore, L1 CAM overexpression in malignant melanoma was shown to be associated with metastases [34] .
According to Oncomine preliminary microarray expression data [17] along with the prevalent CHL1 down-regulation in several tumors (RCC, lung SCC, colon ADC), the overexpression of CHL1 was found in melanoma. The differential expression was observed in lung ADC [26] , cervical [22] and breast [29, 30] cancer.
Based on this data, we hypothesized that CHL1 and other recognition receptors of this type might have dual roles in cancer: in early pre-invasive growth they could serve as TSG and are silenced; later at invasion and metastasis stages these genes might be re-expressed on the edge of the tumor to drive local invasion and enable metastatic spread.
This hypothesis was analyzed in the current study using a combination of preliminary expression screening in 19 different types of epithelial tumors with commercial microarrays (altogether 395 informative samples, Table 1 ) and evaluation of the CHL1 mRNA expression in primary tumors using RT-qPCR. This method is widely used to corroborate disease-associated expression signatures derived from microarrays. Furthermore, this technology is well suited for translating microarrays data into accurate and quantitative, clinically useful assays [37] .
We showed here that the expression of CHL1 was deregulated in major epithelial malignancies (76%, P,0.01, including 54% down-regulation cases according to microarray data). Statistically significant FD values were shown for breast, colon, rectum, thyroid, kidney and small intestine cancer (Table 1) . For three social significant/important cancer types -breast, kidney and lung microarray data were validated by RT-qPCR. There was a good concordance between data of two methods for kidney and breast cancer. According to Oncomine microarray data the significant decrease of CHL1 expression level in CC-RCC samples was shown as well.
Clontech Microarray (overexpression in 64% lung cancer samples) and RT-qPCR (down-regulation in 38% of ADC and in 81% of SCC samples) were not in concord because different cancer subtypes were present in studied microarray samplings.
The disagreement between arrays and RT-qPCR data for NSCLC could also result from non-homogeneous samples with different content of normal cells as well as limited number of specimens and may be statistically non-significant. Although these data are not statistically valid they could reflect important trends and associations.
However there was a rather good agreement between our quantitative results for lung cancer and Oncomine data [17] for two major lung cancer histotypes -ADC and SCC.
It is important to note that Oncomine exploits microarrays based on completely different platform than Clontech Cancer Profiling Arrays. Traditional microarrays (Affymetrix, Agilent) contain a number of various gene probes immobilized on glass slides. Only one cDNA sample can be hybridized with the slide. On the contrary, Clontech Cancer Profiling Arrays contain a number of immobilized cDNA samples from various tumor and normal tissues. Oncomine includes traditional microarrays data making possible genome-wide analysis of a limited number of samples and Cancer Profiling Arrays enable analysis of one gene in many tumors in one experiment.
According to the Clontech Microarray data, the mRNA level increase was observed for several tumor types -uterus, ovary, colon, stomach, thyroid, lung, kidney, and trachea -mainly for non-metastatic tumors. However, also there were frequent cases of the CHL1 mRNA level increase in metastatic tumors, for example, in stomach and lung cancer. Note: *P -p-parameter, characterized the difference between group with metastases and group without metastases, taking into account 3 possible events: decrease, increase and retention of mRNA level in tumor samples comparing to adjusted normal samples. P-parameter calculated using x 2 method. **P -p-parameter, characterized the difference between group of tumor samples and group of adjusted normal samples, taking into account prevalent process (decrease or increase of mRNA level). P-parameter calculated using Fisher exact test for all cancers, except breast cancer. Bold -the most significant changes. doi:10.1371/journal.pone.0015612.t001
Moreover in four metastases (4I, 14O, 14V, 24K) of 12 available for analysis cases (i.e. when a primary tumor and metastasis for the same patient were accessible) we detected an increased CHL1 expression in metastasis compared to primary tumor (ovary, colon and breast). Similar results were recently reported for the metastasis-associated gene lysyl oxidase (LOX), whose expression was associated both with tumor suppression and tumor progression depending on transformation status [32] . The overexpression of another cell adhesion molecule L1 gene was associated with metastasis in malignant melanoma [34] .
Cancer is a fatal disease whereby invasive local tumor growth and metastatic spread to distant vital organs resulting in dormant and/or active growth and inevitable death of patients. Contrary to previous models new evidence suggested that metastatic cells might be created already during initial growth of a primary local tumor. These cells then succeed in cell migration/invasion, embolization, survival in the circulation, arrest in a distant capillary bed, and extravasation into and multiplication within the distant organ parenchyma. Failure at any of these steps could block the entire metastatic process and may lead to ''dormant cancer cells and dormant micrometastases''. Surgical removal of the primary tumor might then lead to active growth [38] . Because tumor spread is responsible for the majority of deaths of cancer patients, the development of therapeutic agents that inhibit tumor metastasis is of paramount importance [39, 40, 41, 42, 43, 44, 45, 46, 47] .
One of us predicted previously [5] that the cytoplasmic end of CHL1 protein might interact with the cytoskeleton and might induce/regulate filopodia formation driving tumor cell migration and invasion [41, 45, 46] . CHL1 behavior in cancer is thus strikingly similar to L1 [10, 40] and LOX which both work through the actin network.
This study suggested that CHL1 might contribute to cancer invasive growth and metastasis. It might act either as a tumor suppressor (early growth) or oncogene (invasive and metastatic growth, Fig. 1 , Table 1 ). CHL1 therefore could belong to the new rapidly growing category of cancer genes that may function either as TSGs or oncogenes [32, 41, 43, 46, 47, 48] . During initial growth CHL1 is not expressed (silenced) in tumor cells to facilitate in situ tumor growth. Re-expression of CHL1 on the edge of the tumor mass and around tumor vessels could promote migration and local invasive growth and furthermore allow initiating the metastatic process. Thus, our results along with the findings that CHL1 was a mutated candidate cancer-associated gene in colon cancer [1] suggested that this type of recognition receptors may indeed have dual roles in carcinogenesis. The mutations discovered in the extra-cellular part of CHL1 could afford a therapeutic antibody to selectively treat patients [1] . This validates CHL1 as a novel target for personalized immune intervention in cancers expressing mutated CHL1. New therapeutic small inhibitors directed at CHL1 could be effective in restraining new tumor formation from dormant micrometastases.
Our results indicated that the CHL1 gene could be important for the development of major human cancers, and also allowed to suggest a hypothesis on a probable dual role of CHL1, although only for three types of cancer (ovary, colon and breast) supportive data were thus far obtained. A frequent decrease of an expression level was prevalent for 11 of 19 tumor types and statistically significant for breast, colon, rectum, thyroid, kidney and small intestine cancer.
Our data also supported the role of CHL1 as a potentially novel biomarker in the early pathogenesis of two major histological types of renal cancer both CC-RCC and pRCC. Results derived with 7 RCC cell lines suggested them as a potential model system for study of methylation role in CHL1 silencing.
Materials and Methods
Cancer profiling arrays analysis
Cancer Profiling Arrays I and II (154 and 241 samples respectively, overall 19 different types of cancers namely, breast, kidney, rectum, colon, stomach, skin, thyroid, small intestine, bladder, vulva, pancreas, prostate, cervix, testis, lung, ovary, uterus, liver, trachea) purchased from BD Biosciences Clontech (Palo Alto, CA), were used to analyze the expression of the CHL1 gene in normal and tumor tissues. Full sample information for Array I and II is presented in Clontech Catalog: No. 7841-1 and No. 631777 respectively (see ''Arrays Information S1'').
We analyzed only informative samples with clear ratio of normal-tumor spots intensity. The information for samples of the Cancer Profiling Array I is presented below. I: 8C, 8F, 8H, 8I, 8J, 8K, 8L, 8M, 8N, 8O, 8P, 8Q, 8R, 8S,  8U, 8X, 8Y, 8BB, 8CC, 8DD, 8EE, 8FF, The arrays were hybridized with specific CHL1 probes labeled with 32 P-a-deoxycytidine triphosphate according to manufacturer's protocol (Clontech). The images were obtained using the Packard Cyclone Storage Phosphor System (PerkinElmer, Shelton, CT).
Tissues specimens and cell lines for RT-qPCR analysis
We analyzed cDNA samples isolated from 30 NSCLC specimens including 16 SCC and 14 ADC; 39 renal cancer specimens including 30 CC-RCC and 9 papillary renal cell carcinomas (pRCC) and 23 breast cancer primary tumors including 19 ductal BC, one lobular BC and 3 mixed lobularductal BC. Accordingly, we used 29, 39 and 23 samples from adjacent morphologically normal lung, renal and breast tissues as controls. Six samples of normal lung tissues from healthy donors were used as additional controls. Paired tumor and noncancerous (normal) matched tissues were received from Blokhin Cancer Research Center, Russian Academy of Medical Sciences. All tumors were classified according to the International TNM Classification system [49, 50] . These samples were obtained from patients after surgical resection of primary lung, renal and breast cancer prior radiation or chemotherapy and stored in liquid nitrogen. The diagnosis was verified by histopathology and only samples containing 70-80% or more tumor cells were used in the study. The samples were collected in accordance to the guidelines issued by the Ethics Committee of Blokhin Cancer Research Center, Russian Academy of Medical Sciences (Moscow). All patients gave written informed consent that is available upon request. The Ethics Committee of Blokhin Cancer Research Center, Russian Academy of Medical Sciences specifically approved this study. The study was done in accordance with the principles outlined in the Declaration of Helsinki.
Clear cell renal cancer cell lines TK10, TK164, KRC/Y, KH39, HN4, Caki1and Caki2 from MTC collection were also analyzed in the study. Mix of six samples of normal lung tissues from healthy donors were used as controls.
RNA and cDNA preparation for RT-qPCR
Total RNA was isolated from tumor and matched normal tissues, renal cancer cell lines using RNeasy Mini Kit (Qiagen, Netherlands) according to the manufacturer's instructions. Purified RNA was quantified using NanoDropH ND-1000 spectrophotometer (NanoDrop Technologies Inc., USA), and the quality was determined by Bioanalyzer 2100 (Agilent Technologies, USA). All RNA samples were treated with DNase I and cDNA was synthesized using MMLV reverse transcriptase and random hexamers according to standard manufacturer's protocol (Fermentas, Lithuania).
Analysis of CHL1 expression by RT-qPCR
RT-qPCR was performed essentially as described previously [51] in total volume of 25 ml in triplicate. The sequences of primers (F and R) and TaqMan probes (Z) are shown in Table 5 . Final concentrations of primers and probes for target and reference genes were as follow: CHL1 primers -300 nM, probe -400 nM; GAPDH primers -300 nM, probe -150 nM, RPN1 primers -300 nM, probe -150 nM, GUSB primers -300 nM, probe -250 nM, B2M primers and probe -300 nM.
The thermocycler conditions were 10 min at 95uC, then 45 two-step cycles 15 s at 95uC and 60 s at 60uC (ABI 7000 PRISM Sequence Detection System, Applied Biosystems). The sequences of the amplicons were verified by sequencing in a 3730 DNA Analyzer (Applied Biosystems).
RT-qPCR data were analyzed using the relative quantification method, or DDC q -method [52, 53] The reaction efficiencies (E) were calculated as described [33] and their values were 8569% (lung), 93611% (breast), 87610% (renal) for CHL1; 8968% (lung) for GAPDH; 86611% (breast) for B2M; 8769% (renal) for RPN1; 8169% (renal) for GUSB in tumor and normal samples. The level of mRNA expression change was calculated as 1/R and reflected the n-fold factor by which the mRNA content decreased or increased in the tumor compared to normal tissue.
All preliminary validation steps were performed according to Gene quantification resource (www.gene-quantification.de). As reference genes, we used GAPDH and RPN1 for NSCLC, B2M for BC, and GUSB and RPN1 for RCC. The relative inner variability between GAPDH, B2M, GUSB and RPN1 mRNA levels was not higher than 2-fold in tumor (T) and normal (N) tissues, therefore 2-fold and more mRNA changes for CHL1 were considered as significant for all types of studied tumors. All calculations performed using our program ATG (Analysis of Transcription of Genes) compatible with Relative Quantification (RQ) software (Applied Biosystems). The program is designed for mathematical processing of RT-qPCR data in paired normaltumor samples. The general features of AEGIS consist of estimating reaction efficiencies with three different methods (including calculating efficiency from kinetic curves) and taking it into account for further data analysis, using the relative comparative DDC q method [52] with several reference genes and estimating their variability. Also this program allows checking adjusted normal samples variability and using as paired normal sample for each tumor sample as one or several normal samples for all tumor samples.
Statistical analysis
For validation of CHL1 expression differences between normal and tumor samples and also between tumor samples with and without metastases we applied Fisher exact test and x 2 criterion. Nonparametric Wilcoxon test was used for analyzing RT-qPCR data to compare mRNA content differences of the CHL1 gene and reference genes for the same samples. We used nonparametric Kruskal-Wallis and Mann-Whitney tests for the rank order differences between average relative levels of mRNA in different groups of samples. P-values,0.05 were considered statistically significant. All statistical procedures were performed using BioStat software [54] .
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